Table 1 Demographics of index isolates included for whole-genome sequencing.
Non-IDU patients, N = 91 | PWID, N = 154 | P | |
|---|---|---|---|
Demographics | |||
Age (mean, SD) | 58 ± 14 | 38 ± 10 | <0.001 |
Female | 34 (37.4%) | 77 (50%) | 0.045 |
Homeless | 0 (0.0%) | 12 (7.8%) | <0.001 |
Discharged AMA | 0 (0.0%) | 43 (27.9%) | <0.001 |
Substance use patterns | |||
Opioid use (fentanyl or heroin) | 0 (0.0%) | 142 (92.2%) | <0.001 |
Methamphetamine use | 0 (0.0%) | 48 (31.1%) | <0.001 |
Comorbidities | |||
Hepatitis B virus infection | 0 (0.0%) | 6 (3.9%) | 0.017 |
Hepatitis C virus infection | 1 (1.1%) | 95 (61.7%) | <0.001 |
HIV Infection | 0 (0.0 %) | 10 (6.5%) | 0.002 |
Elixhauser comorbidities (mean, SD) | 9.0 (3.4) | 8.6 (3.9) | 0.484 |
Clinical syndromes caused by Isolate | |||
Infective endocarditis | 21 (23.0%) | 99 (64.3%) | <0.001 |
Osteomyelitis | 17 (18.6%) | 33 (21.4%) | 0.576 |
Septic arthritis | 10 (10.9%) | 27 (17.5%) | 0.149 |
Necrotizing skin and soft tissue infection | 6 (6.6%) | 22 (14.2%) | 0.054 |
Isolated bacteremia | 46 (50.5%) | 15 (9.7%) | <0.001 |
S. aureus infection characteristics | |||
Hospital Day of S. aureus Isolation for WGS (mean day, SE) | 1 ± 0.2 | 1 ± 0.3 | 0.641 |
Duration of bacteremia (mean days, SE) | 3 ± 0.3 | 4 ± 0.3 | 0.122 |
Central line associated bacteremia | 38 (41.8%) | 1 (0.6%) | <0.001 |
Outcomes | |||
1 year Mortality | 27 (29.7%) | 22 (14.3%) | 0.082 |
